KR101310000B1 - 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 - Google Patents

난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 Download PDF

Info

Publication number
KR101310000B1
KR101310000B1 KR1020077023307A KR20077023307A KR101310000B1 KR 101310000 B1 KR101310000 B1 KR 101310000B1 KR 1020077023307 A KR1020077023307 A KR 1020077023307A KR 20077023307 A KR20077023307 A KR 20077023307A KR 101310000 B1 KR101310000 B1 KR 101310000B1
Authority
KR
South Korea
Prior art keywords
biomarkers
ovarian cancer
hepcidin
cancer
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077023307A
Other languages
English (en)
Korean (ko)
Other versions
KR20080044801A (ko
Inventor
에릭 토마스 풍
로버트 바스트
다니엘 더블유. 찬
진 송
블라디미르 포더스트
젠 장
Original Assignee
싸이퍼젠 바이오시스템즈, 인코포레이티드
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이퍼젠 바이오시스템즈, 인코포레이티드, 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템, 더 존스 홉킨스 유니버시티 filed Critical 싸이퍼젠 바이오시스템즈, 인코포레이티드
Publication of KR20080044801A publication Critical patent/KR20080044801A/ko
Application granted granted Critical
Publication of KR101310000B1 publication Critical patent/KR101310000B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
KR1020077023307A 2005-03-11 2006-03-10 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 Expired - Lifetime KR101310000B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66209005P 2005-03-11 2005-03-11
US60/662,090 2005-03-11
PCT/US2006/008578 WO2006099126A2 (en) 2005-03-11 2006-03-10 Biomarkers for ovarian cancer and endometrial cancer: hepcidin

Publications (2)

Publication Number Publication Date
KR20080044801A KR20080044801A (ko) 2008-05-21
KR101310000B1 true KR101310000B1 (ko) 2013-09-25

Family

ID=36992262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077023307A Expired - Lifetime KR101310000B1 (ko) 2005-03-11 2006-03-10 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘

Country Status (11)

Country Link
US (2) US7510842B2 (https=)
EP (1) EP1869462B1 (https=)
JP (1) JP5069214B2 (https=)
KR (1) KR101310000B1 (https=)
CN (1) CN101189516A (https=)
AU (1) AU2006223374B2 (https=)
CA (1) CA2602088C (https=)
IL (1) IL185496A (https=)
MX (1) MX2007011024A (https=)
NZ (1) NZ560976A (https=)
WO (1) WO2006099126A2 (https=)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP2848942B1 (en) 2004-07-14 2017-03-08 The Regents of The University of California Biomarkers for early detection of ovarian cancer
US9488655B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
US9487575B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP4801930B2 (ja) * 2005-05-02 2011-10-26 株式会社Ｍｃｂｉ 新規肝がんバイオマーカーおよび該バイオマーカーを用いた肝がんの検出方法
JP5159619B2 (ja) * 2005-06-22 2013-03-06 ザ・ジョンズ・ホプキンス・ユニバーシティ 卵巣癌のバイオマーカー：ｃｔａｐ３関連タンパク質
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
US7672916B2 (en) * 2005-08-16 2010-03-02 The Trustees Of Columbia University In The City Of New York Methods, systems, and media for music classification
US7972770B2 (en) 2005-08-16 2011-07-05 Memorial Sloan-Kettering Cancer Center Methods of detection of cancer using peptide profiles
JP2009536313A (ja) 2006-01-11 2009-10-08 レインダンス テクノロジーズ， インコーポレイテッド ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法
ATE540750T1 (de) 2006-05-11 2012-01-15 Raindance Technologies Inc Mikrofluidische vorrichtung und verfahren
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
MX2009000685A (es) * 2006-07-21 2009-01-30 Amgen Inc Metodo para detectar y/o cuantificar hepcidina en una muestra.
EP3536396B1 (en) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008060376A2 (en) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
WO2008048508A2 (en) * 2006-10-13 2008-04-24 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
US20110053268A1 (en) * 2006-10-17 2011-03-03 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
WO2008049175A1 (en) * 2006-10-24 2008-05-02 Katholieke Universiteit Leuven High discriminating power biomarker diagnosing
EP2087152B1 (en) * 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8221984B2 (en) 2007-03-27 2012-07-17 Vermillion, Inc. Biomarkers for ovarian cancer
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2008146903A1 (ja) 2007-05-31 2008-12-04 Naohisa Tomosugi 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
EP2179288A4 (en) * 2007-07-20 2010-07-21 Univ Utah Res Found IDENTIFYING AND QUANTIFYING BIOMARKERS TO EVALUATE THE RISK OF A BREAKFAST
US8039227B2 (en) * 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
WO2009058331A2 (en) * 2007-10-29 2009-05-07 Vermilllion, Inc. Biomarkers for the detection of early stage ovarian cancer
PE20091261A1 (es) 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
CA2705952C (en) * 2007-11-23 2018-05-01 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP2315629B1 (en) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Droplet libraries
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
EA201170312A1 (ru) * 2008-08-06 2012-03-30 Эли Лилли Энд Компани Селективные антитела к гепцидину-25 и их применение
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
EP3415235B1 (en) 2009-03-23 2025-11-12 Bio-Rad Laboratories, Inc. Manipulation of microfluidic droplets
EP2273272A1 (en) 2009-07-06 2011-01-12 Stichting Katholieke Universiteit Method for predicting the outcome of chemotherapy in ovarian cancer
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US9321818B2 (en) * 2010-02-09 2016-04-26 Academia Sinica Dermcidin-derived peptides for lung cancer diagnostics
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
WO2011149942A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
US20120046185A1 (en) * 2010-08-06 2012-02-23 Vermillion, Inc. Panel of biomarkers for ovarian cancer
CN102375063A (zh) * 2010-08-23 2012-03-14 湖州赛尔迪生物医药科技有限公司 一种常见蛋白质的免疫质谱试剂盒及制备方法
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
CA2818593A1 (en) * 2010-10-22 2012-04-26 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
EP3736281A1 (en) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
JP6078067B2 (ja) 2011-08-29 2017-02-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用
EP3495817B1 (en) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molecular diagnostic screening assay
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR102155531B1 (ko) 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
EP3524693A1 (en) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digital analyte analysis
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
US9657098B2 (en) * 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
TWI598577B (zh) * 2014-03-28 2017-09-11 梅托珍尼克斯股份有限公司 Method for obtaining data for determining possibility of carcinogenesis of endometriotic ovarian cysts, and diagnostic apparatus thereof
EP2955517A1 (de) * 2014-06-10 2015-12-16 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Stabilisierung von Körperflüssigkeitsproben durch die Zugabe von Detergenz
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP2017535750A (ja) * 2014-09-24 2017-11-30 マップ アイピー ホールディング リミテッド 妊娠の予後を提供する方法
GB2530521B (en) * 2014-09-24 2020-06-10 Map Ip Holding Ltd Mass spectral analysis of patient samples for the detection of the human chorionic gonadotropin
US10392665B2 (en) 2015-06-19 2019-08-27 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN106872593B (zh) * 2017-02-04 2021-05-04 江西省妇幼保健院 溶血磷脂酸作为标志物在检测子宫内膜异位症中的应用
EP4530633A3 (en) 2017-08-18 2026-03-25 Sera Prognostics, Inc. Pregnancy clock proteins for predicting due date and time to birth
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
KR102633621B1 (ko) 2017-09-01 2024-02-05 벤 바이오사이언시스 코포레이션 진단 및 치료 모니터링용 바이오마커로서의 당펩티드의 식별 및 용도
CN108152430A (zh) * 2017-12-21 2018-06-12 上海中科新生命生物科技有限公司 基于prm检测的卵巢癌标志物检测试剂盒及检测方法
WO2021168040A1 (en) * 2020-02-19 2021-08-26 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
US20230280349A1 (en) * 2022-03-01 2023-09-07 The University Of Chicago Methods of Differentiating a Malignant Tumor from a Non-Malignant Tumor
WO2024119119A1 (en) * 2022-12-02 2024-06-06 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
WO2024192014A1 (en) * 2023-03-12 2024-09-19 Novelna Inc. Endometrial cancer detection proteins and methods of use thereof
CN119757576A (zh) * 2024-12-26 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于区分健康与宫颈癌的代谢标志物组合及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058044A2 (en) * 2002-11-19 2004-07-15 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
AU2003235749A1 (en) * 2002-01-07 2003-07-24 John Hopkins University Biomarkers for detecting ovarian cancer
NZ562192A (en) * 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US7670792B2 (en) * 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058044A2 (en) * 2002-11-19 2004-07-15 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor

Also Published As

Publication number Publication date
CN101189516A (zh) 2008-05-28
EP1869462A2 (en) 2007-12-26
US20070054329A1 (en) 2007-03-08
EP1869462B1 (en) 2013-05-08
WO2006099126A3 (en) 2006-12-07
CA2602088A1 (en) 2006-09-21
JP2008533471A (ja) 2008-08-21
WO2006099126A2 (en) 2006-09-21
IL185496A0 (en) 2008-01-06
KR20080044801A (ko) 2008-05-21
US7510842B2 (en) 2009-03-31
MX2007011024A (es) 2009-11-23
AU2006223374B2 (en) 2011-07-21
NZ560976A (en) 2011-06-30
AU2006223374A1 (en) 2006-09-21
EP1869462A4 (en) 2009-01-14
IL185496A (en) 2012-07-31
JP5069214B2 (ja) 2012-11-07
CA2602088C (en) 2021-07-27
US20100068724A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
KR101310000B1 (ko) 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
JP5159619B2 (ja) 卵巣癌のバイオマーカー：ｃｔａｐ３関連タンパク質
US8465929B2 (en) Biomarkers for ovarian cancer
US20210181207A1 (en) Biomarkers for Ovarian Cancer: B2 Microglobulin
WO2005098447A2 (en) Biomarkers for ovarian cancer
US20100055690A1 (en) Prognostic biomarkers in patients with ovarian cancer
US20140038837A1 (en) Biomarkers for the detection of early stage ovarian cancer
US8221984B2 (en) Biomarkers for ovarian cancer
AU2015210343B2 (en) BIOMARKERS FOR OVARIAN CANCER: ß-2 MICROGLOBULIN
US20150153348A1 (en) BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110302

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120921

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130620

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130911

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130911

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160829

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160829

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170830

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170830

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20180827

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190829

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190829

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20200828

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210827

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220826

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20230829

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20240827

Start annual number: 12

End annual number: 12